Stavudine

also known as d4T · Zerit · BMY 27857 · d4T XR · 2',3'-dideoxy-2',3'-didehydrothymidine · 2',3'-Didehydro-2',3'-Dideoxythymidine · 2',3'-Didehydro-3'-Deoxythymidine · d4T ER · +9 more

Other / unclassified

Developed for: HIV infectious disease · AIDS · AIDS dementia complex · Kaposi's sarcoma · lactic acidosis
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Bristol-Myers Squibb · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Merck Sharp & Dohme LLC · Gilead Sciences · Glaxo Wellcome
+41 more
· Triangle Pharmaceuticals · AIDS Care Research in Africa · Boehringer Ingelheim · Dupont Merck · Makerere University · Ministry of Science and Technology of the People´s Republic of China · Peking Union Medical College · Pharmacia and Upjohn · AIDS Malignancy Consortium · Botswana Ministry of Health · CIHR Canadian HIV Trials Network · Cipla Medpro · Department of Foreign Affairs, Ireland · Dermatological Society of South Africa · Doris Duke Charitable Foundation · GlaxoSmithKline · Groupe Hospitalier Pitie-Salpetriere · HIV Prevention Trials Network · Harvard School of Public Health (HSPH) · Hoffmann-La Roche · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Kirby Institute · Mbarara University of Science and Technology · McGill University Health Centre/Research Institute of the McGill University Health Centre · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Research Foundation, Singapore · PENTA Foundation · PPD Development, LP · Princess Marina Hospital, Botswana · Shanghai Public Health Clinical Center · St Vincent's Hospital, Sydney · The Wistar Institute · University of British Columbia · University of Cape Town · University of KwaZulu · University of Minnesota · University of North Carolina, Chapel Hill · University of Zimbabwe · Weill Medical College of Cornell University

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (4)	US (FDA)	ZERIT	—	1995-12-21 – 2002-03-29	fda.gov ↗
Approved	EU (EMA)	Zerit	—	1996-05-08	europa.eu ↗
Approved	US (FDA)	ZERIT	—	1994-06-24	fda.gov ↗

Trials 91 · started per year

today

US approved 1994

EU approved 1996

1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials
Phase 1	NCT00001108	? → Jun 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00001091	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000902	? → Apr 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000865	? → Apr 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00004736	—	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000878	? → Oct 2001	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000988	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002381	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00000686	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00312091	Dec 2006 → Sep 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 228 trials
Phase 2	NCT00000940	May 1999 → Oct 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001688	Jan 1998 → Nov 2001	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00001095	? → Oct 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002379	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00000885	? → Jun 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00036452	? → Jan 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000891	? → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001063	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002184	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00002241	—	HIV infectious disease	Merck Sharp & Dohme LLC	Unknown	No outcome recorded
Phase 2	NCT00000851	? → Oct 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00006339	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT00000831	? → May 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000918	? → Feb 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00007202	? → Oct 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000882	? → May 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002420	—	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 2	NCT00002227	—	HIV infectious disease	Dupont Merck	Completed	No outcome recorded
Phase 2	NCT00001067	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000924	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001083	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000789	? → Jul 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002451	—	HIV infectious disease	Merck Sharp & Dohme LLC	Unknown	No outcome recorded
Phase 2	NCT00000838	? → Mar 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002225	—	HIV infectious disease	Dupont Merck	Completed	No outcome recorded
Phase 2	NCT00000916	? → Aug 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002418	—	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2/3	NCT00143702	Aug 2001 → Aug 2006	lactic acidosis	University of British Columbia	Completed	No outcome recorded
Phase 314 trials
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00197613	Dec 2002 → Dec 2007	AIDS	Harvard School of Public Health (HSPH)	Completed	No outcome recorded
Phase 3	NCT00135369	Sep 2002 → Jul 2005	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00116298	Jan 2001 → Jan 2005	AIDS	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00006397	Aug 2000 → ?	HIV infectious disease	PPD Development, LP	Unknown	No outcome recorded
Phase 3	NCT00006208	Aug 2000 → ?	HIV infectious disease	Triangle Pharmaceuticals	Unknown	No outcome recorded
Phase 3	NCT00005918	Jun 2000 → Apr 2002	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00002429	Jul 1999 → Jan 2001	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00002246	Oct 1997 → Mar 1999	AIDS dementia complex, HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00002371	Jun 1996 → Dec 1997	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00050895	? → Mar 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002208	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00002374	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded

Phase 416 trials
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT01075152	Nov 2010 → Oct 2012	AIDS, Cryptococcal meningitis	University of Minnesota	Completed	No outcome recorded
Phase 4	NCT00753324	May 2009 → Jan 2012	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT00872417	Mar → Dec 2009	AIDS	Peking Union Medical College	Unknown	No outcome recorded
Phase 4	NCT00455585	Jan → May 2007	HIV infectious disease	Makerere University	Completed	No outcome recorded
Phase 4	NCT00618176	Jan 2005 → Sep 2006	HIV infectious disease	Peking Union Medical College	Completed	No outcome recorded
Phase 4	NCT00235222	Jun 2004 → Mar 2006	HIV infectious disease	Groupe Hospitalier Pitie-Salpetriere	Unknown	No outcome recorded
Phase 4	NCT00055120	Mar 2003 → Sep 2006	AIDS-related disorder, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00380770	Jan 2003 → Feb 2009	AIDS, Kaposi's sarcoma, human herpesvirus 8 infection	University of KwaZulu	Completed	No outcome recorded
Phase 4	NCT00116116	Mar 2002 → Jun 2005	AIDS	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00006190	Nov 2000 → Nov 2001	HIV infectious disease, lipodystrophy	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 4	NCT00005106	Sep 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00002386	—	HIV infectious disease, hemophilia A	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00002376	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00005017	—	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded

Phase not applicable21 trials
—	NCT01344148	Feb 2009 → Jun 2011	AIDS	Shanghai Public Health Clinical Center	Unknown	No outcome recorded
—	NCT00100646	Mar 2007 → Mar 2010	HIV infectious disease	The Wistar Institute	Completed	No outcome recorded
—	NCT00830856	Oct 2006 → Oct 2008	Cryptococcal meningitis, HIV infectious disease	University of Zimbabwe	Completed	No outcome recorded
—	NCT00080522	Feb 2005 → Jan 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002411	Mar 1998 → Sep 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002177	May 1997 → Mar 2000	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002176	May 1997 → Mar 2000	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002349	Jan 1995 → May 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00006443	? → Oct 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000896	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002308	? → Nov 1991	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00000922	? → Jan 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002407	—	HIV infectious disease	Weill Medical College of Cornell University	Completed	No outcome recorded
—	NCT00002168	—	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002307	? → Dec 1994	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002369	—	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00014937	? → Dec 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002211	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded
—	NCT00002354	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00000919	? → Nov 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00004855	? → Apr 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 57 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT00032669 Background	Mar 2002 → Apr 2006	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00002427 Background	May 1999 → ?	HIV infectious disease	Research Institute for Genetic and Human Therapy	Completed	No outcome recorded
Phase 1	NCT00000899 Background	? → Oct 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000822 Background	? → May 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000901 Background	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00004578 Comparator	Nov 1997 → Apr 2005	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 216 trials
Phase 2	NCT00651066 Background	Jun 2010 → Sep 2012	HIV infectious disease, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00640887 Background	Feb 2009 → Oct 2010	HIV infectious disease, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT01174914 Comparator	Mar 2008 → Mar 2010	—	The Ojai Foundation	Completed	No outcome recorded
Phase 2	NCT00006144 Background	Oct 2000 → Apr 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002442 Background	Jun 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00002240 Background	Mar 1999 → Dec 2001	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT02249130 Background	Mar 1999 → Apr 2000	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00000870 Background	? → Mar 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001084 Background	? → Dec 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00017992 Background	—	HIV infectious disease	Triangle Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT00001087 Background	? → Jul 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002162 Background	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00000939 Background	? → Jan 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002412 Background	—	HIV infectious disease	Triangle Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00002424 Background	—	HIV infectious disease	Merck Sharp & Dohme LLC	Suspended	No outcome recorded
Phase 2	NCT00001122 Background	? → Oct 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT02016924 Background	Jan 2014 → Jun 2025 overdue	AIDS	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2/3	NCT00495326 Comparator	Dec 2007 → Apr 2011	AIDS, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 317 trials
Phase 3	NCT02670772 Comparator	Jul 2012 → Dec 2014	AIDS	Willem Daniel Francois Venter	Completed	No outcome recorded
Phase 3	NCT01605084 Background	Jun 2012 → Aug 2014	HIV infectious disease	Bristol-Myers Squibb	Withdrawn	No outcome recorded
Phase 3	NCT01252940 Background	Nov 2010 → Jan 2012	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01146873 Comparator	Jul 2010 → Dec 2014	AIDS	Columbia University	Completed	No outcome recorded
Phase 3	NCT00978068 Comparator	Sep 2009 → Jan 2013	HIV infectious disease, malaria	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00427297 Background	Sep 2007 → May 2009	HIV infectious disease	University of Washington	Terminated	No outcome recorded
Phase 3	NCT00528957 Comparator	Dec 2006 → Apr 2009	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00650637 Background	Jan → Aug 2003	diarrheal disease	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00002362 Background	Aug 1999 → ?	HIV infectious disease	Triangle Pharmaceuticals	Suspended	No outcome recorded
Phase 3	NCT00004583 Background	Mar 1999 → ?	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 3	NCT00002224 Background	Mar 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00006154 Comparator	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002109 Background	—	HIV infectious disease	Immunobiology Research Institute	Completed	No outcome recorded
Phase 3	NCT00002230 Background	—	HIV infectious disease	Northwestern University	Completed	No outcome recorded
Phase 3	NCT00000841 Background	? → Jun 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002378 Background	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00002397 Background	—	HIV infectious disease, HIV-associated nephropathy	Hoffmann-La Roche	Completed	No outcome recorded

Phase 48 trials
Phase 4	NCT01192035 Comparator	May 2011 → Sep 2014	—	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT01601899 Comparator	Oct 2008 → Oct 2010	metabolic disease	University of Witwatersrand, South Africa	Terminated	No outcome recorded
Phase 4	NCT00617643 Background	May 2008 → Jun 2009	HIV infectious disease, tuberculosis	Makerere University	Completed	No outcome recorded
Phase 4	NCT00084253 Comparator	Jun 2004 → Aug 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00127972 Background	Feb 2004 → Apr 2007	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00342355 Comparator	Jan 2004 → Mar 2008	HIV infectious disease	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 4	NCT02300623 Background	Mar 2000 → Apr 2013	HIV infectious disease	Juan A. Arnaiz	Completed	No outcome recorded
Phase 4	NCT00005000 Background	Dec 1999 → ?	HIV infectious disease	Agouron Pharmaceuticals	Unknown	No outcome recorded

Phase not applicable8 trials
—	NCT02002286 Background	Aug 2011 → May 2013	HIV infectious disease	LI Taisheng	Completed	No outcome recorded
—	NCT00428116 Comparator	Sep 2007 → Jul 2013	HIV infectious disease	University of Washington	Terminated	No outcome recorded
—	NCT00255840 Comparator	Jul 2006 → Jan 2009	HIV infectious disease	CIPRA SA	Completed	No outcome recorded
—	NCT00002207 Background	Feb 2004	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00006441 Background	Feb 2003 → Oct 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002430 Background	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00000923 Background	? → Aug 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00034086 Background	? → Jun 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2003-02-11	Gilead Sciences	96-Week Data From Phase III Study Show Long-Term Efficacy With Reduced Risk of Lipid and Metabolic Changes for Viread Versus Stavudine in Treatment-Naive HIV Patients gilead.com ↗
2002-07-08	Gilead Sciences	48-Week Data Compare Viread to Stavudine When Used as Part of Patients' First Anti-HIV Regimen; Data Presented at XIV International AIDS Conference in Barcelona gilead.com ↗
2002-05-07	Gilead Sciences	Gilead Announces Preliminary 48-Week Study Results Showing Viread Comparable to Stavudine in Treatment-Naive HIV Patients gilead.com ↗

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 155 sources stand behind the page.

Field	Value	Cited text
Known as	stavudine	“It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ 144 “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286 ↗ “Triomune is manufactured by a generic drug company and consists of three drugs combined in a single pill given twice daily (stavudine 30mg plus lamivudine 150mg plus nevirapine 200mg).” NCT00617643 ↗ “Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)” NCT00380770 ↗ “The Fixed Drug Combination (FDC) nevirapine (NVP)-lamivudine-stavudine is the first line ART available for low-income countries.” NCT00495326 ↗ “lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);” NCT00650637 ↗ “Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.” NCT00978068 ↗ “Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.” NCT00006441 ↗ “In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T).” NCT00753324 ↗ “or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI” NCT01192035 ↗ “lamivudine/zidovudine (3TC/AZT), stavudine (d4T)” NCT00039741 ↗ “Stavudine + lamivudine + nevirapine (TRIOMUNE)Or” NCT01174914 ↗ “d4T/3TC/NVP (stavudine/lamivudine/nevirapine)” NCT00428116 ↗ “the second line is Stavudine(D4T)+3TC+EFV” NCT01344148 ↗ “regimen with stavudine XR and lamivudine” NCT00084253 ↗ “Stavudine (30 mg or 40 mg)” NCT01605084 ↗ “zidovudine or stavudine” NCT01075152 ↗ “d4T (stavudine)” NCT00143702 ↗ “stavudine (d4T)” NCT02016924 ↗ “stavudine (d4T)” NCT06337032 ↗ “Stavudine” NCT02300623 ↗ NCT00002362 ↗ NCT00002184 ↗ NCT00000822 ↗ NCT00255840 ↗ NCT00192660 ↗ NCT00002354 ↗ NCT00074581 ↗ NCT00055120 ↗ NCT00197613 ↗ NCT00004578 ↗ NCT00000940 ↗ NCT00135369 ↗ NCT02670772 ↗ NCT00000918 ↗ NCT00235222 ↗ NCT00002411 ↗ NCT00002109 ↗ NCT00000870 ↗ NCT00002442 ↗ NCT00001067 ↗ NCT00000831 ↗ NCT00000882 ↗ NCT00002427 ↗ NCT00006144 ↗ NCT00002225 ↗ NCT00312091 ↗ NCT00002308 ↗ NCT00001108 ↗ NCT00004736 ↗ NCT00006397 ↗ NCT00000924 ↗ NCT00002386 ↗ NCT01601899 ↗ NCT00002376 ↗ NCT00005017 ↗ NCT02249130 ↗ NCT00005106 ↗ NCT01146873 ↗ NCT00002224 ↗ NCT00000838 ↗ NCT00001091 ↗ NCT00002162 ↗ NCT00000988 ↗ NCT00000789 ↗ NCT00000923 ↗ NCT00002412 ↗ NCT00002207 ↗ NCT00002349 ↗ NCT00002168 ↗ NCT00427297 ↗ NCT00002371 ↗ NCT00000865 ↗ NCT00000872 ↗ NCT00017992 ↗ NCT00002208 ↗ NCT00002451 ↗ NCT00001083 ↗ NCT00528957 ↗ NCT00002241 ↗ NCT00455585 ↗ NCT00002420 ↗ NCT00002230 ↗ NCT00001084 ↗ NCT00000939 ↗ NCT00002418 ↗ NCT00342355 ↗ NCT00127972 ↗ NCT00002424 ↗ NCT00002211 ↗ NCT00002176 ↗ NCT00007202 ↗ NCT00080522 ↗ NCT00000878 ↗ NCT00034086 ↗ NCT00005000 ↗ NCT00116116 ↗ NCT00001087 ↗ NCT00001688 ↗ NCT00002240 ↗ NCT00002374 ↗ NCT00000841 ↗ NCT00002407 ↗ NCT00830856 ↗ NCT00002369 ↗ NCT00002379 ↗ NCT00014937 ↗ NCT00004855 ↗ NCT00006208 ↗ NCT00618176 ↗ NCT00005918 ↗ NCT00013520 ↗ NCT00006443 ↗ NCT00002429 ↗ NCT00002246 ↗ NCT00002307 ↗ NCT00050895 ↗ NCT00116298 ↗ NCT00001063 ↗ NCT00000901 ↗ NCT00000902 ↗ NCT00002227 ↗ NCT00002397 ↗ NCT00001122 ↗ NCT00000919 ↗ NCT00000896 ↗ NCT00000686 ↗ NCT00002378 ↗ NCT00000851 ↗ NCT00006190 ↗ NCT00000885 ↗ NCT00002430 ↗ NCT00000899 ↗ NCT00000916 ↗ NCT00100646 ↗ NCT00001095 ↗ NCT00004583 ↗ NCT00006154 ↗ NCT00002177 ↗ NCT00002381 ↗ NCT00036452 ↗ NCT00000922 ↗ NCT00006339 ↗ NCT00000891 ↗
Known as	2',3'-Didehydro-2',3'-Dideoxythymidine	“A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With...” NCT00002308 ↗
Known as	2',3'-Didehydro-3'-Deoxythymidine	“A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex” NCT00000988 ↗
Known as	2',3'-dideoxy-2',3'-didehydrothymidine	“To evaluate the safety, minimum effective dose (MED), pharmacokinetics and efficacy of orally administered 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) in patients with AIDS or...” NCT00000988 ↗ 1 “A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex” NCT00000686 ↗
Known as	BMY 27857	“A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between...” NCT00002307 ↗ 2 “A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex” NCT00000686 ↗ “A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex” NCT00000988 ↗
Known as	d4T	“The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations,...” NCT00116298 ↗ 84 “In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T...” PMID 11880966 ↗ Feb 2002 “A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With...” NCT00002308 ↗ “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir...” NCT00002397 ↗ “An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1...” NCT00002381 ↗ “Arm I options are enteric-coated didanosine (ddI-EC) plus lamivudine (3TC), ddI-EC plus zidovudine (ZDV), ZDV plus 3TC (or Combivir), stavudine (d4T) plus 3TC, or ddI-EC plus...” NCT00014937 ↗ “Double reverse transcriptase inhibitor (RTI) therapy consisting of any two therapy combinations of: didanosine (ddI), lamivudine (3TC), stavudine (d4T) or zidovudine (ZDV),...” NCT00002376 ↗ “The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken...” NCT00005918 ↗ “adding stavudine (d4T) to anti-HIV drug regimens (with or without zidovudine, ZDV) can improve symptoms of AIDS Dementia Complex (ADC, problems involving the brain or spinal...” NCT00002246 ↗ “To evaluate the safety, minimum effective dose (MED), pharmacokinetics and efficacy of orally administered 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) in patients with AIDS or...” NCT00000988 ↗ “The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the...” NCT00002241 ↗ “A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between...” NCT00002307 ↗ “Subjects (2 to <16 years) on a stavudine (d4T) or zidovudine (ZDV) containing regimen with HIV-1 RNA <400 copies/mL were randomized to either switch d4T or ZDV to TDF or...” PMID 25760565 ↗ Apr 2015 “The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to...” NCT00000901 ↗ “The nucleoside analogue combinations provided on this study are as follows: zidovudine (ZDV) plus didanosine (ddI), ZDV plus lamivudine (3TC), stavudine (d4T) plus 3TC, or d4T plus ddI.” NCT00000923 ↗ “To compare the effect of stavudine (d4T) alone or with zidovudine (AZT) versus didanosine (ddI) alone or with AZT on CD4 counts, HIV RNA levels, and viral load in HIV-infected patients” NCT00001063 ↗ “Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV).” NCT00000919 ↗ “The 7 drugs that will be given in this study are stavudine (d4T), didanosine (ddI), lamivudine (3TC), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and nevirapine (NVP).” NCT00001108 ↗ “This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC).” NCT00002424 ↗ “A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex” NCT00000686 ↗ “A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection” NCT00002176 ↗ “A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.” NCT00002349 ↗ “A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants” NCT00000878 ↗ “Arm A Stavudine (d4T) 30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte” NCT01601899 ↗ “A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection” NCT00000789 ↗ “The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.” NCT00002412 ↗ “efavirenz (EFV) or lopinavir/ritonavir (LPV/r) with either zidovudine (ZDV) plus didanosine (ddI) or stavudine (d4T) plus lamivudine (3TC)” PMID 20942650 ↗ Oct 2010 “In Step 1 of this 2-step protocol, all patients receive a HAART regimen of nelfinavir (NFV) plus stavudine (d4T) plus lamivudine (3TC).” NCT00000899 ↗ “Patients who develop intolerance to AZT or have progressive disease after 24 weeks on study may substitute stavudine ( d4T ) for AZT.” NCT00000841 ↗ “Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults” NCT00002427 ↗ “efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI)” NCT00000838 ↗ “Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)” NCT00495326 ↗ “The study-specified NRTIs will be abacavir (ABC) plus lamivudine (3TC) or didanosine (ddI) plus stavudine (d4T).” NCT00000922 ↗ “Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo or Zidovudine (ZDV) + Lamivudine + Stavudine placebo” NCT00002371 ↗ “The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).” NCT00002211 ↗ “The drug combination will contain didanosine (ddI) plus stavudine (d4T) plus nevirapine (NVP) plus MKC-442.” NCT00002418 ↗ “3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);” NCT00651066 ↗ “Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.” NCT00002407 ↗ “emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), lopinavir/ritonavir (LPV/RTV), and stavudine (d4T)” NCT00055120 ↗ “Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY” NCT00235222 ↗ “indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC)” NCT00002451 ↗ “NFV 50-55 mg/kg bid, nevirapine (NVP) 120 mg/m bid and stavudine (d4T) 1 mg/kg bid (arm B)” PMID 16220085 ↗ Oct 2005 “Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.” NCT00006441 ↗ “Other medications which may be added include didanosine (ddI) and/or stavudine (d4T).” NCT00000916 ↗ “In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T).” NCT00753324 ↗ “combination drug therapy with didanosine (ddI), stavudine (d4T), and efavirenz (DMP)” NCT00002230 ↗ “Arm A receives stavudine (d4T) plus didanosine (ddI) plus ritonavir plus indinavir.” NCT00006339 ↗ “Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).” NCT00002224 ↗ “D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks)” NCT00640887 ↗ “taking didanosine (ddI) once a day plus stavudine (d4T) twice a day” NCT00002207 ↗ “combination therapy with ritonavir, nevirapine and stavudine (d4T)” NCT00001688 ↗ “stavudine (d4T) alone and in combination with didanosine (ddI)” NCT00000851 ↗ “zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC)” NCT00001095 ↗ “stavudine (d4T), didanosine (ddI), and BMS-232632” NCT00007202 ↗ “lamivudine/zidovudine (3TC/AZT), stavudine (d4T)” NCT00039741 ↗ “lamivudine (3TC)/abacavir (ABC)/stavudine (d4T)” NCT00005017 ↗ “d4T/3TC/NVP (stavudine/lamivudine/nevirapine)” NCT00427297 ↗ “d4T/3TC/NVP (stavudine/lamivudine/nevirapine)” NCT00428116 ↗ “the second line is Stavudine(D4T)+3TC+EFV” NCT01344148 ↗ “Stavudine (d4T) 30mg bid” NCT00618176 ↗ “Stavudine (d4T)” NCT00002354 ↗ “stavudine (d4T)” NCT02016924 ↗ “stavudine (d4T)” NCT00006144 ↗ “stavudine (d4T)” NCT00002442 ↗ “stavudine (d4T)” NCT00312091 ↗ “stavudine (d4T)” NCT00002386 ↗ “Stavudine (d4T)” NCT02249130 ↗ “Stavudine (D4T)” NCT01146873 ↗ “stavudine (d4T)” NCT00006397 ↗ “stavudine (d4T)” NCT00005000 ↗ “stavudine (d4T)” NCT00002420 ↗ “stavudine (d4T)” NCT00000896 ↗ “stavudine (d4T)” NCT00002362 ↗ “Stavudine (d4T)” NCT00000865 ↗ “stavudine (d4T)” NCT00001122 ↗ “stavudine (d4T)” NCT00000891 ↗ “stavudine (d4T)” NCT06337032 ↗ “d4T (Stavudine)” NCT00002177 ↗ “Stavudine (d4T)” NCT00000882 ↗ “stavudine (d4T)” NCT00006443 ↗ “stavudine (d4T)” NCT00004736 ↗ “stavudine, d4T” NCT00002208 ↗ NCT00143702 ↗ NCT00872417 ↗
Known as	d4T ER	“Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation.” NCT00005918 ↗
Known as	d4T IR	“Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation.” NCT00005918 ↗
Known as	d4T XR	“Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release...” NCT00116116 ↗ 2 “Arms A, B, and C receive the same daily dosage of lopinavir/ritonavir (LPV/r), emtricitabine (FTC), and stavudine extended release (d4T XR) or tenofovir DF (TDF).” NCT00036452 ↗ “stavudine extended release (d4T XR) once daily” NCT00050895 ↗
Known as	Estavudina	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	NSC-163661	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	NSC-759897	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	Sanilvudine	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	Stavudine (d4t)	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	Stavudine (dt4)	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	Stavudinum	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Known as	Zerit	“An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1...” NCT00002381 ↗ 3 “100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) +...” NCT00002369 ↗ “Zerit (Stavudine)” NCT00002168 ↗ “Zerit (Stavudine)” NCT00002420 ↗
Known as	Zerit xr	ChEMBL registry synonym — accepted as the source's own label CHEMBL991 ↗
Action	Inhibit	“Test-tube and animal studies of d4T show that the drug can inhibit replication (reproduction) of HIV” NCT00000686 ↗
Modality	Other / unclassified	“HIV nucleoside reverse transcriptase inhibitors (NRTI)” PMID 16103764 ↗ Sep 2005
Route	Oral	“oral dosing” NCT00000686 ↗